Fox Chase Cancer Center News

PHILADELPHIA (January 19, 2021)—Elizabeth Plimack, MD, MS, professor in the Department of Hematology/Oncology and chief of the Division of Genitourinary Medical Oncology at Fox Chase Cancer Center, has been appointed chair of the Scientific Advisory Board (SAB) for the Bladder Cancer Advocacy Network (BCAN).

PHILADELPHIA (January 11, 2021) – Fox Chase Cancer Center is pleased to announce the addition of Joel Helmke, MSHP, FACHE, to its senior leadership team as chief operating officer (COO). Helmke’s tenure will begin on February 1, 2021.

PHILADELPHIA (January 11, 2021) – Fox Chase Cancer Center is pleased to announce the recruitment of Anna Liza Rodriguez, MSN, MHA, RN, OCN®, NEA-BC, as chief nursing officer (CNO) and vice president of nursing and patient services. Rodriguez’s start date is February 1, 2021.

PHILADELPHIA (January 5, 2021) – Joshua E. Meyer, MD, associate professor in the Department of Radiation Oncology at Fox Chase Cancer Center, has been awarded a grant to investigate the role of local consolidative therapy with radiation in the second-line treatment of metastatic colorectal cancer.

PHILADELPHIA (December 29, 2020) – Researchers at Fox Chase Cancer Center recently published a study outlining the center’s 30 years of experience with a rare form of pancreatic cancer.

PHILADELPHIA (December 28, 2020)–Researchers at Fox Chase Cancer Center have identified a potential new target, a tyrosine kinase known as Wee1, for the treatment of gastrointestinal stromal tumor (GIST).

PHILADELPHIA (December 23, 2020)—Researchers at Fox Chase Cancer Center have published research showing that perceiving positive life changes, known as “benefit finding,” is common among colorectal cancer (CRC) patients, especially women and racial minorities. Benefit finding is thought to promote better adjustment after cancer, yet is poorly understood in colorectal cancer.

PHILADELPHIA (December 16, 2020)—A team of scientists from Fox Chase Cancer Center received a pilot award from the Melanoma Research Alliance (MRA) for a research project that will investigate a new drug target for the treatment of melanoma that combines aspects of epigenetics and immunotherapy.